Kiniksa Pharmaceuticals International (KNSA) Income from Continuing Operations (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Income from Continuing Operations for 10 consecutive years, with $25.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Income from Continuing Operations rose 42.62% year-over-year to $25.4 million; the trailing twelve-month figure through Jun 2026 stood at $80.7 million (up 1583.88% YoY), and the FY2025 full-year result was $59.0 million, up 236.61% from the prior year.
• Income from Continuing Operations rose to $25.4 million in Q2 2026 per KNSA's latest filing, from $22.6 million in the prior quarter.
• Across five years, Income from Continuing Operations topped out at $224.1 million in Q3 2022 and bottomed at -$49.2 million in Q4 2023.
• Historically, Income from Continuing Operations has averaged $15.0 million across 5 years, with a median of $2.3 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations jumped 833.67% in 2022, then plunged 155.63% in 2023.
• Over 5 years, Income from Continuing Operations stood at $88.5 million in 2022, then plunged by 155.63% to -$49.2 million in 2023, then soared by 81.95% to -$8.9 million in 2024, then surged by 259.75% to $14.2 million in 2025, then jumped by 79.11% to $25.4 million in 2026.
• According to Business Quant data, Income from Continuing Operations over the past three periods registered $25.4 million, $22.6 million, and $14.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.